 |
Photo: ABL Bio |
[Alpha Biz= Ellie Kim] Compass Therapeutics has reported that its bile duct cancer treatment candidate “Tovecimig” (ABL001) failed to meet certain key endpoints in a Phase 2/3 clinical trial.
According to ABL Bio on the 28th, its global partner Compass Therapeutics released results from a study involving 168 patients.
Data showed that when Tovecimig was used in combination with the chemotherapy drug paclitaxel, the median progression-free survival (PFS) reached 4.7 months, compared to 2.6 months for paclitaxel alone.
Thomas Schuetz, CEO of Compass Therapeutics, said the company plans to meet with the U.S. Food and Drug Administration (FDA) and submit a Biologics License Application (BLA) seeking approval for use as a second-line treatment for bile duct cancer.
However, the trial did not meet its secondary endpoint of overall survival (OS). The median OS for the combination therapy was 8.9 months, shorter than the 9.4 months observed with paclitaxel alone.
ABL Bio explained that the OS comparison was limited due to crossover, noting that 31 patients in the control group were switched to the combination therapy, which may have affected the results.
Alphabiz Ellie Kim 인턴기자(press@alphabiz.co.kr)
